FY2027 Earnings Forecast for CRSP Issued By Zacks Research

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities researchers at Zacks Research issued their FY2027 earnings estimates for shares of CRISPR Therapeutics in a note issued to investors on Tuesday, March 4th. Zacks Research analyst R. Department expects that the company will post earnings per share of ($4.62) for the year. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

A number of other brokerages have also weighed in on CRSP. Citigroup cut their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research note on Tuesday, February 18th. Chardan Capital cut their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. The Goldman Sachs Group cut their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $73.11.

Remove Ads

CRISPR Therapeutics Price Performance

CRSP traded up $2.22 during trading on Wednesday, reaching $45.53. The company had a trading volume of 1,884,937 shares, compared to its average volume of 2,267,393. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $81.73. The business's fifty day moving average price is $42.79 and its 200 day moving average price is $45.79. The company has a market cap of $3.91 billion, a P/E ratio of -10.42 and a beta of 1.67.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CRSP. Boston Family Office LLC boosted its position in shares of CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock valued at $459,000 after acquiring an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC boosted its position in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock valued at $1,238,000 after acquiring an additional 218 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after acquiring an additional 231 shares during the period. Intellectus Partners LLC boosted its position in shares of CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock valued at $281,000 after acquiring an additional 250 shares during the period. Finally, Farrow Financial Inc. boosted its position in shares of CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after acquiring an additional 270 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Greene acquired 7,000 shares of the firm's stock in a transaction on Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the acquisition, the director now owns 7,000 shares of the company's stock, valued at approximately $313,950. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.